SUBUTEX sublingual tablet is indicated for the treatment of opioid dependence and is preferred for induction. Patients should Buy Subutex Online from Dr Che Pharmacy. We are FDA approved so Buy Subutex Online from us. SUBUTEX sublingual tablet should be used as part of a complete treatment plan to include counseling and psychosocial support. Do not miss this golden opportunity to Buy Subutex Online from us.
Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription
Prescription use of this product is limited under the Drug Addiction
Treatment Act. (2.1)
Administer SUBOXONE sublingual film as a single daily dose.
To avoid precipitating withdrawal, induction with SUBOXONE sublingual film should be undertaken when objective and clear signs of withdrawal are evident and SUBOXONE sublingual film should be administered in divided doses when used as initial treatment.
For patients dependent on short‐acting opioid products who are in opioid withdrawal; on Day 1, administer up to 8 mg/2 mg SUBOXONE sublingual film (in divided doses). On Day 2, administer up to 16 mg/4 mg of SUBOXONE sublingual film as a single dose.
For patients dependent on methadone or long‐acting opioid products, induction onto sublingual buprenorphine monotherapy is recommended on Days 1 and 2 of treatment.
For maintenance treatment, the target dosage of SUBOXONE sublingual film is usually 16 mg/4 mg as a single daily dose.
Sublingual Administration: Place one film under the tongue, close to the base on the left or right side, and allow to completely dissolve. Buccal Administration: Place one film on the inside of the left or right
cheek and allow to completely dissolve.
SUBOXONE sublingual film must be administered whole. Do not cut, chew, or swallow SUBOXONE sublingual film.
When discontinuing treatment, gradually taper to avoid signs and
symptoms of withdrawal.
Adverse events commonly observed with the sublingual/buccal administration of the SUBOXONE sublingual film are oral hypoesthesia, glossodynia, oral mucosal erythema, headache, nausea, vomiting,
hyperhidrosis, constipation, signs and symptoms of withdrawal, insomnia, pain, and peripheral edema.
DOSAGE FORMS AND STRENGTHS
buprenorphine 2 mg/ naloxone 0.5 mg,
buprenorphine 4 mg/ naloxone 1 mg,
buprenorphine 8 mg/ naloxone 2 mgand
buprenorphine 12 mg/ naloxone 3 mg.
Hypersensitivity to buprenorphine or naloxone.
Buprenorphine can be abused in a manner similar to other opioids, legal or illicit. Prescribe and dispense buprenorphine with appropriate precautions to
minimize risk of misuse, abuse, or diversion, and ensure appropriate protection from theft, including in the home. Clinical monitoring appropriate to the
patient’s level of stability is essential. Multiple refills should not be prescribed early in treatment or without appropriate patient follow-up visits.